CovidChloroV1, Main, Corpus, bibRecord, 000740

Rise and Fall: Hydroxychloroquine and COVID-19 Global Trends: Interest, Political Influence, and Potential Implications.

Identifieur interne : 000740 ( Main/Corpus ); précédent : 000739; suivant : 000741

Rise and Fall: Hydroxychloroquine and COVID-19 Global Trends: Interest, Political Influence, and Potential Implications.

Auteurs : Tessa R. Englund ; Alan C. Kinlaw ; Saira Z. Sheikh

Source :

ACR open rheumatology [ 2578-5745 ] ; 2020.

RBID : pubmed:33263947

Abstract

OBJECTIVE

The coronavirus disease 2019 (COVID-19) pandemic has led to rapid research and reporting on potential preventatives and treatments for the disease, including the drug hydroxychloroquine (HCQ). Despite a lack of robust evidence to support the use of HCQ for treatment of COVID-19, it was publicly endorsed and received widespread media coverage and public interest. The purpose of this report is to describe and contextualize the surges in public interest, demand, and adoption of HCQ for treatment of COVID-19 and outline implications for future public health policy and practice.

METHODS

Using national and global events and Google Trends data as a measure of public interest, we describe the timeline and trends in the emergence of, interest in, and adoption of HCQ as a treatment of COVID-19. We additionally review reports on public demand for HCQ for treatment of COVID-19 and impacts on medication access among patients with indicated uses.

RESULTS

Public interest and demand for HCQ surged in the United States and globally following endorsements from public officials and enaction of policies to facilitate off-label use of HCQ for treatment of COVID-19. Surges in demand for HCQ led to multiple documented shortages and barriers to accessing HCQ treatment for patients with indicated uses for HCQ. Although there have been reversals in policies to support HCQ use for treatment of COVID-19 in some regions, others have continued or expanded recommended uses.

CONCLUSION

Insights from the global response to HCQ and COVID-19 can be used to inform prudent decision-making in the future to prevent premature action and promote informed and equitable responses to promote public health.

DOI: 10.1002/acr2.11207
PubMed: 33263947
PubMed Central: PMC7738805

Links to Exploration step

pubmed:33263947

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rise and Fall: Hydroxychloroquine and COVID-19 Global Trends: Interest, Political Influence, and Potential Implications.</title>
<author><name sortKey="Englund, Tessa R" sort="Englund, Tessa R" uniqKey="Englund T" first="Tessa R" last="Englund">Tessa R. Englund</name>
<affiliation><nlm:affiliation>University of North Carolina at Chapel Hill.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kinlaw, Alan C" sort="Kinlaw, Alan C" uniqKey="Kinlaw A" first="Alan C" last="Kinlaw">Alan C. Kinlaw</name>
<affiliation><nlm:affiliation>University of North Carolina at Chapel Hill.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Sheikh, Saira Z" sort="Sheikh, Saira Z" uniqKey="Sheikh S" first="Saira Z" last="Sheikh">Saira Z. Sheikh</name>
<affiliation><nlm:affiliation>University of North Carolina at Chapel Hill.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:33263947</idno>
<idno type="pmid">33263947</idno>
<idno type="doi">10.1002/acr2.11207</idno>
<idno type="pmc">PMC7738805</idno>
<idno type="wicri:Area/Main/Corpus">000740</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000740</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Rise and Fall: Hydroxychloroquine and COVID-19 Global Trends: Interest, Political Influence, and Potential Implications.</title>
<author><name sortKey="Englund, Tessa R" sort="Englund, Tessa R" uniqKey="Englund T" first="Tessa R" last="Englund">Tessa R. Englund</name>
<affiliation><nlm:affiliation>University of North Carolina at Chapel Hill.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kinlaw, Alan C" sort="Kinlaw, Alan C" uniqKey="Kinlaw A" first="Alan C" last="Kinlaw">Alan C. Kinlaw</name>
<affiliation><nlm:affiliation>University of North Carolina at Chapel Hill.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Sheikh, Saira Z" sort="Sheikh, Saira Z" uniqKey="Sheikh S" first="Saira Z" last="Sheikh">Saira Z. Sheikh</name>
<affiliation><nlm:affiliation>University of North Carolina at Chapel Hill.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">ACR open rheumatology</title>
<idno type="eISSN">2578-5745</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b>
</p>
<p>The coronavirus disease 2019 (COVID-19) pandemic has led to rapid research and reporting on potential preventatives and treatments for the disease, including the drug hydroxychloroquine (HCQ). Despite a lack of robust evidence to support the use of HCQ for treatment of COVID-19, it was publicly endorsed and received widespread media coverage and public interest. The purpose of this report is to describe and contextualize the surges in public interest, demand, and adoption of HCQ for treatment of COVID-19 and outline implications for future public health policy and practice.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>METHODS</b>
</p>
<p>Using national and global events and Google Trends data as a measure of public interest, we describe the timeline and trends in the emergence of, interest in, and adoption of HCQ as a treatment of COVID-19. We additionally review reports on public demand for HCQ for treatment of COVID-19 and impacts on medication access among patients with indicated uses.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>Public interest and demand for HCQ surged in the United States and globally following endorsements from public officials and enaction of policies to facilitate off-label use of HCQ for treatment of COVID-19. Surges in demand for HCQ led to multiple documented shortages and barriers to accessing HCQ treatment for patients with indicated uses for HCQ. Although there have been reversals in policies to support HCQ use for treatment of COVID-19 in some regions, others have continued or expanded recommended uses.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSION</b>
</p>
<p>Insights from the global response to HCQ and COVID-19 can be used to inform prudent decision-making in the future to prevent premature action and promote informed and equitable responses to promote public health.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33263947</PMID>
<DateRevised><Year>2020</Year>
<Month>12</Month>
<Day>19</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2578-5745</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>2</Volume>
<Issue>12</Issue>
<PubDate><Year>2020</Year>
<Month>Dec</Month>
</PubDate>
</JournalIssue>
<Title>ACR open rheumatology</Title>
<ISOAbbreviation>ACR Open Rheumatol</ISOAbbreviation>
</Journal>
<ArticleTitle>Rise and Fall: Hydroxychloroquine and COVID-19 Global Trends: Interest, Political Influence, and Potential Implications.</ArticleTitle>
<Pagination><MedlinePgn>760-766</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/acr2.11207</ELocationID>
<Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The coronavirus disease 2019 (COVID-19) pandemic has led to rapid research and reporting on potential preventatives and treatments for the disease, including the drug hydroxychloroquine (HCQ). Despite a lack of robust evidence to support the use of HCQ for treatment of COVID-19, it was publicly endorsed and received widespread media coverage and public interest. The purpose of this report is to describe and contextualize the surges in public interest, demand, and adoption of HCQ for treatment of COVID-19 and outline implications for future public health policy and practice.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Using national and global events and Google Trends data as a measure of public interest, we describe the timeline and trends in the emergence of, interest in, and adoption of HCQ as a treatment of COVID-19. We additionally review reports on public demand for HCQ for treatment of COVID-19 and impacts on medication access among patients with indicated uses.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Public interest and demand for HCQ surged in the United States and globally following endorsements from public officials and enaction of policies to facilitate off-label use of HCQ for treatment of COVID-19. Surges in demand for HCQ led to multiple documented shortages and barriers to accessing HCQ treatment for patients with indicated uses for HCQ. Although there have been reversals in policies to support HCQ use for treatment of COVID-19 in some regions, others have continued or expanded recommended uses.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Insights from the global response to HCQ and COVID-19 can be used to inform prudent decision-making in the future to prevent premature action and promote informed and equitable responses to promote public health.</AbstractText>
<CopyrightInformation>© 2020 The Authors. ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Englund</LastName>
<ForeName>Tessa R</ForeName>
<Initials>TR</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0003-0418-7434</Identifier>
<AffiliationInfo><Affiliation>University of North Carolina at Chapel Hill.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kinlaw</LastName>
<ForeName>Alan C</ForeName>
<Initials>AC</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0002-4279-8685</Identifier>
<AffiliationInfo><Affiliation>University of North Carolina at Chapel Hill.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sheikh</LastName>
<ForeName>Saira Z</ForeName>
<Initials>SZ</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0003-4128-0443</Identifier>
<AffiliationInfo><Affiliation>University of North Carolina at Chapel Hill.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>12</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>ACR Open Rheumatol</MedlineTA>
<NlmUniqueID>101740025</NlmUniqueID>
<ISSNLinking>2578-5745</ISSNLinking>
</MedlineJournalInfo>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>08</Month>
<Day>28</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>11</Month>
<Day>06</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>12</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>12</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>12</Month>
<Day>2</Day>
<Hour>12</Hour>
<Minute>9</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">33263947</ArticleId>
<ArticleId IdType="doi">10.1002/acr2.11207</ArticleId>
<ArticleId IdType="pmc">PMC7738805</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Expert Rev Clin Immunol. 2020 Jul;16(7):659-666</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32620062</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Rheumatol. 2020 Jul;2(7):e390</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32835242</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Intern Med. 2020 Oct 20;173(8):623-631</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32673060</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2020 Oct;20(10):1118-1119</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32311324</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Intern Med. 2020 Dec 1;173(11):W156-W157</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33085507</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>ACR Open Rheumatol. 2020 Jun;2(6):335-343</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32311836</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Res Social Adm Pharm. 2014 Nov-Dec;10(6):896-903</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24603135</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 May 2;395(10234):1410</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32359456</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Jun 27;395(10242):1967</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32539936</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Intern Med. 2020 Oct 20;173(8):654-655</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32543882</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Intern Med. 2020 Oct 20;173(8):662-663</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32673059</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2014 Feb 15;383(9917):630-67</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24524782</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Jul 7;324(1):31-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32271871</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Rep. 2016 Sep 06;6:32920</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27595921</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JMIR Public Health Surveill. 2020 May 21;6(2):e19702</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32401211</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Mal Infect. 2020 May;50(3):229-230</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32217166</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Jun 20;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32562416</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Intern Med. 2020 Jun 16;172(12):819-821</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32227189</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2020 Apr 1;369:m1335</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32238355</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>ACR Open Rheumatol. 2019 Oct 18;1(9):593-599</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31777844</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Intern Med. 2020 Aug 1;180(8):1116-1118</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32347895</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MMWR Morb Mortal Wkly Rep. 2020 Sep 04;69(35):1210-1215</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32881845</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Rheum Dis. 2020 May 20;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32434820</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Manag Care. 2010 Aug;16(8):e215-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20690788</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Rheumatol. 2019 Nov;31(6):689-696</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31436582</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Rheumatol. 2020 Nov;39(11):3205-3213</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32996071</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000740 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000740 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:33263947
   |texte=   Rise and Fall: Hydroxychloroquine and COVID-19 Global Trends: Interest, Political Influence, and Potential Implications.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i   -Sk "pubmed:33263947" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Rise and Fall: Hydroxychloroquine and COVID-19 Global Trends: Interest, Political Influence, and Potential Implications.

Rise and Fall: Hydroxychloroquine and COVID-19 Global Trends: Interest, Political Influence, and Potential Implications.

Source :

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki